Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 262

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Guidelines on the use and monitoring of heparin

Baglin, T., Barrowcliffe, T. W., Cohen, A., Greaves, M, the British Committee for Standards in Haematology·2006·British Journal of Haematology

Abstract

The guideline group was selected to be representative of UK-based medical experts. The drafting group met and communicated by e-mail. Draft guidelines were revised by consensus. Since the initial guideline published by the British Committee for Standards in Haematology (BCSH; Colvin & Barrowcliffe, 1993) evidence-based guidelines on the use and monitoring of heparin have been included in the American College of Chest Physicians Consensus Conferences on Antithrombotic Therapy (ACCP; Hirsh & Raschke, 2004) and the Scottish Intercollegiate Guidelines Network (SIGN; http://www.sign.ac.uk/guidelines/fulltext/36/section12.html). Reference to these guidelines is advised for a comprehensive review of the evidence. The recommendations in this BCSH guideline generally reflect those of the ACCP and SIGN and are updated where appropriate to encompass recent studies. The guideline was reviewed by a multidisciplinary sounding board, the BCSH and the British Society for Haematology (BSH) and comments incorporated where appropriate. Criteria used to quote levels and grades of evidence are as in Appendix 3 of the Procedure for Guidelines Commissioned by the BCSH (http://www.bcshguidelines.com). The target audience for this guideline is healthcare professionals involved in the management of patients receiving heparin. This guideline will be reviewed in 2008. Interim addendums will be published as required on the BCSH website (http://www.bcshguidelines.com). Heparin remains the most widely used parenteral antithrombotic. The general adoption of low-molecular weight heparins (LMWHs) represents a significant therapeutic advance in terms of ease and convenience of administration. There may also be some advantages in terms of efficacy and fewer side-effects. A further development has been the introduction into clinical practice of the synthetic pentasaccharide factor Xa inhibitor, fondaparinux. This compound may have additional advantages although its role in prophylaxis and treatment has yet to be fully defined. Heparin is a naturally occurring glycosaminoglycan produced by the mast cells of most species. The pharmaceutical drug is extracted from porcine or bovine mucosa. All the products currently used in the United Kingdom are of porcine origin. Heparin consists of alternating chains of uronic acid and glucosamine, sulphated to varying degrees, and has a molecular weight (MW) range of 5000–35 000 Da. Samples of heparin over the last 50 years have shown a steady rise in MW with a concomitant rise in specific activity (Mulloy et al, 2000); current preparations have a mean MW of about 13 000–15 000 Da and specific activity of 180–220 IU/mg. Although unfractionated heparin (UFH) is still employed, for many indications there has been a trend towards use of fractionated or LMWHs. These are manufactured from UFH by controlled depolymerisation using chemical (nitrous acid or alkaline hydrolysis) or enzymatic (heparinase) methods. Although the processes yield different end groups, there is no evidence that these differences in chemical structure affect biological function. The biological properties of any LMWH are primarily determined by its MW distribution. As shown in Table I, the products currently available for clinical use have an average MW between 3000 and 5000 Da. They are heterogeneous in MW, although the polydispersity is less than that of UFH and 60–80% of the total polysaccharides lie between MW 2000 and 8000 Da. All anticoagulant properties of UFH and LMWH depend on the presence of a specific pentasaccharide sequence, which binds with high affinity to antithrombin and potentiates its activity (Lindahl et al, 1979). This sequence is present in about one-third of the chains in UFH but in lower proportions in LMWHs because some of these sequences are destroyed by the depolymerisation process. Acceleration of inhibition of factor Xa (anti-Xa activity) requires only the pentasaccharide sequence (approximate MW 1700 Da), but potentiation of thrombin inhibition [anti-IIa activity, also prolongation of activated partial thromboplastin time (APTT)] requires a minimum total chain length of 18 saccharides (MW approximately 5400 Da; Lane et al, 1984). Therefore, in all LMWH preparations the anti-Xa activity exceeds the anti-IIa activity. The ratio of anti-Xa to anti-IIa activity varies between 1·6 to 4·2 for all except one product, which has the lowest MW and an anti-Xa to anti-IIa ratio of 9·6 (Table I). There has been much debate about the relative importance of anti-Xa and anti-IIa activity in the anticoagulant effect of LMWHs in vivo. Biochemical studies have shown that the fractions with anti-IIa activity are largely responsible for the inhibition of thrombin generation in plasma (Béguin et al, 1988). However, fractions with only anti-Xa activity have antithrombotic activity in animals, including the synthetic pentasaccharide, which has now been shown to be an effective antithrombotic agent in clinical trials (Buller et al, 2003)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2005.05953.x

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 85 references

Cited by

See all 262

Metadata

Authors
Baglin, T., Barrowcliffe, T. W., Cohen, A., Greaves, M., & the British Committee for Standards in Haematology
Venue
British Journal of Haematology
Publisher
Wiley
Published
2006-03-02
Volume
133
Issue
1
Pages
19-34
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1993893409
Cited by
262
References
85
FWCI
11.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Guidelines on the use and monitoring of heparin. https://app.cochat.ai/papers/10.1111/j.1365-2141.2005.05953.x
The paper
Baglin, T., Barrowcliffe, T. W., Cohen, A., Greaves, M., & the British Committee for Standards in Haematology. (2006). Guidelines on the use and monitoring of heparin. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2005.05953.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.